Taiwan Pei-Jiun Chen, CEO and President of Mycenax, outlines the company’s evolution into a focused, end-to-end biologics CDMO with deep roots in development excellence and GMP manufacturing. She highlights Japan as Mycenax’s core market, expansion into Europe, disciplined capacity growth, automation-driven productivity, and a niche, customer-centric model supporting complex biologics and…
Taiwan The co-founder and president of Mycenax Biotech, Dr. Karen Wen details the key lessons learned from the development of their first in-house product TuNEX® and how they have been applied to their second flagship product LusiNEX (tocilizumab). She also details the company’s transition from a platform-driven service provider to a…
See our Cookie Privacy Policy Here
